Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Plasmacytoid dendritic cells develop from Ly6D+ lymphoid progenitors distinct from the myeloid lineage.

Dress RJ, Dutertre CA, Giladi A, Schlitzer A, Low I, Shadan NB, Tay A, Lum J, Kairi MFBM, Hwang YY, Becht E, Cheng Y, Chevrier M, Larbi A, Newell EW, Amit I, Chen J, Ginhoux F.

Nat Immunol. 2019 Jul;20(7):852-864. doi: 10.1038/s41590-019-0420-3. Epub 2019 Jun 18.

PMID:
31213723
2.

RIG-I Activation by a Designer Short RNA Ligand Protects Human Immune Cells against Dengue Virus Infection without Causing Cytotoxicity.

Ho V, Yong HY, Chevrier M, Narang V, Lum J, Toh YX, Lee B, Chen J, Tan EY, Luo D, Fink K.

J Virol. 2019 Jun 28;93(14). pii: e00102-19. doi: 10.1128/JVI.00102-19. Print 2019 Jul 15.

3.

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C.

Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.

PMID:
30698644
4.

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.

Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21.

PMID:
30249507
5.

Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.

Harris BD, Schreiter J, Chevrier M, Jordan JL, Walter MR.

J Biol Chem. 2018 Oct 12;293(41):16057-16068. doi: 10.1074/jbc.RA118.003617. Epub 2018 Aug 31.

PMID:
30171073
6.

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.

Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, DePrimo SE, Muñoz-Elías EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA.

J Invest Dermatol. 2018 Sep;138(9):1973-1981. doi: 10.1016/j.jid.2018.03.1501. Epub 2018 Mar 17.

PMID:
29559344
7.

A self-assembly toolbox for thiophene-based conjugated polyelectrolytes: surfactants, solvent and copolymerisation.

Houston JE, Chevrier M, Appavou MS, King SM, Clément S, Evans RC.

Nanoscale. 2017 Nov 16;9(44):17481-17493. doi: 10.1039/c7nr06169b.

PMID:
29106435
8.

Complex US adnexal masses during pregnancy: Is pelvic MR imaging accurate for characterization?

Thomassin-Naggara I, Fedida B, Sadowski E, Chevrier MC, Chabbert-Buffet N, Ballester M, Tavolaro S, Darai E.

Eur J Radiol. 2017 Aug;93:200-208. doi: 10.1016/j.ejrad.2017.05.024. Epub 2017 May 22.

PMID:
28668416
9.

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).

Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Muñoz-Elías EJ, Callis Duffin K.

Br J Dermatol. 2017 Dec;177(6):1552-1561. doi: 10.1111/bjd.15722. Epub 2017 Nov 16.

PMID:
28600818
10.

Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy.

Grellier Adedjouma N, Chevrier M, Fourquet A, Costa E, Xu H, Berger F, Campana F, Laki F, Beuzeboc P, Lefeuvre D, Fournier-Bidoz N, Kirova YM.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):206-214. doi: 10.1016/j.ijrobp.2017.01.205. Epub 2017 Jan 27.

PMID:
28586961
11.

Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.

Chevrier M, Bobbala D, Villalobos-Hernandez A, Khan MG, Ramanathan S, Saucier C, Ferbeyre G, Geha S, Ilangumaran S.

BMC Cancer. 2017 Feb 24;17(1):157. doi: 10.1186/s12885-017-3141-8.

12.

Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.

Huffstutter JE, Kafka S, Brent LH, Matucci-Cerinic M, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ.

Curr Med Res Opin. 2017 Apr;33(4):657-666. doi: 10.1080/03007995.2016.1277195. Epub 2017 Jan 25.

PMID:
28035867
13.

Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group.

Fumery M, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet JM, Boschetti G, Cotte E, Buisson A, Dubois A, Pariente B, Zerbib P, Chafai N, Stefanescu C, Panis Y, Marteau P, Pautrat K, Sabbagh C, Filippi J, Chevrier M, Houze P, Jouven X, Treton X, Allez M; REMIND study group investigators.

Am J Gastroenterol. 2017 Feb;112(2):337-345. doi: 10.1038/ajg.2016.541. Epub 2016 Dec 13.

PMID:
27958285
14.

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group.

Gastroenterology. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3.

15.

High-Permittivity Conjugated Polyelectrolyte Interlayers for High-Performance Bulk Heterojunction Organic Solar Cells.

Kesters J, Govaerts S, Pirotte G, Drijkoningen J, Chevrier M, Van den Brande N, Liu X, Fahlman M, Van Mele B, Lutsen L, Vanderzande D, Manca J, Clément S, Von Hauff E, Maes W.

ACS Appl Mater Interfaces. 2016 Mar;8(10):6309-14. doi: 10.1021/acsami.6b00242. Epub 2016 Mar 3.

16.

Expanding the light absorption of poly(3-hexylthiophene) by end-functionalization with π-extended porphyrins.

Chevrier M, Richeter S, Coulembier O, Surin M, Mehdi A, Lazzaroni R, Evans RC, Dubois P, Clément S.

Chem Commun (Camb). 2016 Jan 4;52(1):171-4. doi: 10.1039/c5cc06290j.

PMID:
26506849
17.

Breast Biopsies Under Magnetic Resonance Imaging Guidance: Challenges of an Essential but Imperfect Technique.

Chevrier MC, David J, Khoury ME, Lalonde L, Labelle M, Trop I.

Curr Probl Diagn Radiol. 2016 May-Jun;45(3):193-204. doi: 10.1067/j.cpradiol.2015.07.002. Epub 2015 Jul 10. Review.

PMID:
26272705
18.

Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G.

J Drugs Dermatol. 2015 Jul;14(7):706-14.

PMID:
26151787
19.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K, Fakharzadeh S, Calabro S, Chevrier M, Langholff W, You Y, Leonardi CL.

JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.

PMID:
25970800
20.

Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

Gottlieb AB, Kalb RE, Langley RG, Krueger GG, de Jong EM, Guenther L, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Menter A.

J Drugs Dermatol. 2014 Dec;13(12):1441-8.

PMID:
25607786
21.

WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G.

J Am Acad Dermatol. 2015 Jan 9. pii: S0190-9622(14)02102-1. doi: 10.1016/j.jaad.2014.10.025. [Epub ahead of print]

PMID:
25582533
22.

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).

Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Menter A; PSOLAR Steering Committee.

Br J Dermatol. 2014 Jul;171(1):137-47. doi: 10.1111/bjd.13013. Epub 2014 Jul 16.

23.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
24.

Structural abnormalities in patients with insular/peri-insular epilepsy: spectrum, frequency, and pharmacoresistance.

Chevrier MC, Bard C, Guilbert F, Nguyen DK.

AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2152-6. doi: 10.3174/ajnr.A3636. Epub 2013 Jun 27.

25.

Postoperative imaging after lung transplantation.

Diez Martinez P, Pakkal M, Prenovault J, Chevrier MC, Chalaoui J, Gorgos A, Ferraro P, Poirier C, Chartrand-Lefebvre C.

Clin Imaging. 2013 Jul-Aug;37(4):617-23. doi: 10.1016/j.clinimag.2013.02.008. Epub 2013 Apr 2. Review.

PMID:
23557663
26.

Insular ischemic stroke: clinical presentation and outcome.

Lemieux F, Lanthier S, Chevrier MC, Gioia L, Rouleau I, Cereda C, Nguyen DK.

Cerebrovasc Dis Extra. 2012 Jan;2(1):80-7. doi: 10.1159/000343177. Epub 2012 Oct 18.

27.

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee.

J Drugs Dermatol. 2012 Oct;11(10):1210-7.

PMID:
23134986
28.

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.

Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M.

J Am Acad Dermatol. 2012 Oct;67(4):642-50. doi: 10.1016/j.jaad.2011.10.020. Epub 2011 Dec 9.

PMID:
22153792
29.

Modernizing confidence-building measures for the Biological Weapons Convention.

Koblentz GD, Chevrier MI.

Biosecur Bioterror. 2011 Sep;9(3):232-8. doi: 10.1089/bsp.2011.0023. Epub 2011 Aug 5.

PMID:
21819226
30.

Autophagosome maturation is impaired in Fabry disease.

Chévrier M, Brakch N, Céline L, Genty D, Ramdani Y, Moll S, Djavaheri-Mergny M, Brasse-Lagnel C, Annie Laquerrière AL, Barbey F, Bekri S.

Autophagy. 2010 Jul;6(5):589-99. doi: 10.4161/auto.6.5.11943. Epub 2010 Jul 1.

PMID:
20431343
31.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

32.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

33.

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.

Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W.

Arthritis Rheum. 2008 Aug;58(8):2453-9. doi: 10.1002/art.23678.

34.

Conflict resolution in a different culture.

Winter FD, Chevrier MI.

Proc (Bayl Univ Med Cent). 2008 Jul;21(3):300-3. No abstract available.

35.

Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay.

Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, Delage G.

Transfusion. 2007 Oct;47(10):1794-802.

PMID:
17880603
36.

Establishment of an immunoglobulin A-deficient blood donor registry with a simple in-house screening enzyme-linked immunosorbent assay.

Thibault L, Beauséjour A, de Grandmont MJ, Long A, Goldman M, Chevrier MC.

Transfusion. 2006 Dec;46(12):2115-21.

PMID:
17176323
37.

Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro.

Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS.

Clin Diagn Lab Immunol. 2005 May;12(5):575-80.

38.

Sensitive detection of human IgG in ELISA using a monoclonal anti-IgG-peroxidase conjugate.

Chevrier MC, Châteauneuf I, Guérin M, Lemieux R.

Hybrid Hybridomics. 2004 Dec;23(6):362-7.

PMID:
15684663
39.

Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.

Lin Y, Yang X, Chevrier MC, Craven S, Barrowcliffe TW, Lemieux R, Ofosu FA.

Haemophilia. 2004 Sep;10(5):459-69.

PMID:
15357771
40.

The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents.

Guilloteau JP, Mathieu M, Giglione C, Blanc V, Dupuy A, Chevrier M, Gil P, Famechon A, Meinnel T, Mikol V.

J Mol Biol. 2002 Jul 26;320(5):951-62.

PMID:
12126617
41.

[Measurement of the quality of life in chronic hepatitis C: validation of a general index and specific index. First French results].

Remy AJ, Daurès JP, Tanguy G, Khemissa F, Chevrier M, Lezotre PL, Blanc P, Larrey D.

Gastroenterol Clin Biol. 1999 Dec;23(12):1296-309. French.

42.

[Accreditation follows dynamic changes. Interview by Marie Hetier].

Chevrier M.

Soins Pediatr Pueric. 1998 Nov;(184):suppl I-III. French. No abstract available.

PMID:
10410102
43.

Diesel exhaust particles are taken up by human airway epithelial cells in vitro and alter cytokine production.

Boland S, Baeza-Squiban A, Fournier T, Houcine O, Gendron MC, Chévrier M, Jouvenot G, Coste A, Aubier M, Marano F.

Am J Physiol. 1999 Apr;276(4):L604-13. doi: 10.1152/ajplung.1999.276.4.L604.

PMID:
10198358
44.

"L'accreditation s'inscrit dans une dynamique de changement".

Chevrier M.

Soins. 1998 Nov;(630):suppl 1-3. French. No abstract available.

PMID:
10095729
45.

Dynamic O-GlcNAcylation of the small heat shock protein alpha B-crystallin.

Roquemore EP, Chevrier MR, Cotter RJ, Hart GW.

Biochemistry. 1996 Mar 19;35(11):3578-86.

PMID:
8639509
46.

Evidence for restricted diversity of antigen-specific human antibodies in immunized hu-PBL-SCID mice.

Bazin R, Chevrier MC, Delage R, Lemieux R.

Hum Antibodies Hybridomas. 1996;7(3):129-34.

PMID:
9057061
47.

Induction of LFA-1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand.

Néron S, Pelletier A, Chevrier MC, Monier G, Lemieux R, Darveau A.

Immunol Invest. 1996 Jan-Mar;25(1-2):79-89.

PMID:
8675236
48.

Preliminary Studies of in vitro and in vivo Effects of Misoprostol on Th-1 and Th-2 Cytokine Production.

Rus V, Nguyen P, Chevrier M, Stair R, Via CS.

Am J Ther. 1995 Dec;2(12):911-916.

PMID:
11854807
49.

Use of hu-IgG-SCID mice to evaluate the in vivo stability of human monoclonal IgG antibodies.

Bazin R, Boucher G, Monier G, Chevrier MC, Verrette S, Broly H, Lemieux R.

J Immunol Methods. 1994 Jun 24;172(2):209-17.

PMID:
7518484
50.

Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M.

Dong DL, Xu ZS, Chevrier MR, Cotter RJ, Cleveland DW, Hart GW.

J Biol Chem. 1993 Aug 5;268(22):16679-87.

Supplemental Content

Loading ...
Support Center